A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection

Drug Safety

Volumn 15, Issue 1, 1996, Pages 30-52

  Hackelsberger, Andreas ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; BISMUTH CITRATE; BISMUTH DERIVATIVE; BISMUTH SALICYLATE; CIPROFLOXACIN; CLARITHROMYCIN; CLAVULANIC ACID; CLINDAMYCIN; DOXYCYCLINE; ERYTHROMYCIN; HISTAMINE H2 RECEPTOR ANTAGONIST; METRONIDAZOLE; NITROFURANTOIN; OFLOXACIN; OMEPRAZOLE; PENICILLIN DERIVATIVE; PROTON PUMP INHIBITOR; RANITIDINE; RANITIDINE BISMUTH CITRATE; TETRACYCLINE; TINIDAZOLE;

ABDOMINAL PAIN; ANAPHYLAXIS; ATAXIA; CANDIDIASIS; CHOLESTASIS; CONSTIPATION; DIARRHEA; DROWSINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; DYSGEUSIA; FATIGUE; FLATULENCE; GASTROINTESTINAL INFECTION; GLOSSITIS; HEADACHE; HELICOBACTER PYLORI; HUMAN; MYALGIA; NAUSEA; ORAL DRUG ADMINISTRATION; PERIPHERAL NEUROPATHY; PHOTODERMATOSIS; PRIORITY JOURNAL; PSEUDOMEMBRANOUS COLITIS; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; SIDE EFFECT; SMOKING; STOMATITIS; TREATMENT FAILURE;

EID: 0029935990     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-199615010-00003     Document Type: Review

References (277)

1. Warren JR. Unidentified curved bacilli on gastric epithelium in active chronic gastritis [letter]. Lancet 1983; 1: 1273
2. Marshall B. Unidentified curved bacilli on gastric epithelium in active chronic gastritis [Letter]. Lancet 1983; 1: 1273-5
3. Rauws EAJ. Therapeutic attempts at eradication of Campylobacter pylori. Eur J Gastroenterol Hepatol 1989; 1: 34-41
4. Ormand JE, Talley NJ. Helicobacter pylori: controversies and an approach to management. Mayo Clin Proc 1990; 65: 414-26
5. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9
6. Graham DY, Lew GM, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6
7. Goodwin CS. Duodenal ulcer, Campylobacter pylori and the 'leaking roof' concept. Lancet 1988; II: 1467-9
8. Leiß O. Chronisch aktive Helicobacter pylori Gastritis: Wann belassen - wann behandeln - wann heilen? Verdauungs-krankheiten 1992; 10: 144-7
9. Borody TJ. Possibilities for Helicobacter pylori suppression/eradication. Eur J Gastroenterol Hepatol 1992; 4 Suppl 2: 37-40
10. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol 1993; 28 Suppl. 196: 34-7
11. Labenz J, Leverkus F, Borsch G. Omeprazole plus amoxycillin for cure of Helicobacter pylori infection: factors influencing the treatment success Scand J Gastroenterol 1994; 29: 1070-5
12. Korman MG, Hansky J, Eaves ER, et al. Influence of cigarette smoking on healing and relapse in duodenal ulcer disease. Gastroenterology 1983; 85: 871-4
13. Hull DH, Beale PJ. Cigarette smoking and duodenal ulcer. Gut 1985; 26: 1333-7
14. Armstrong D, Arnold R, Classen M, et al. Prospective multicentre study of risk factors associated with delayed healing of recurrent duodenal ulcers. Gut 1993; 34: 1319-26
15. Armstrong D, Arnold R, Classen M, et al. Ruder: a prospective, two-year, multicenter study of risk factors for duodenal ulcer relapse during maintenance therapy with ranitidine. Dig Dis Sci 1994; 39: 1425-33
16. Reynolds JC, Schoen RE, Maislin G, et al. Risk factors for delayed healing of duodenal ulcers treated with famotidine and ranitidine. Am J Gastroenterol 1994; 89: 571-80
17. Unge P, Gad A, Eriksson K, et al. Amoxicillin added to omeprazole prevents relapse in the treatment of duodenal ulcer patients. Eur J Gastroenterol Hepatol 1993; 5: 325-31
18. Zala G, Giezendanner S, Flury R, et al. Omeprazole/amoxicillin: beinträchtigte Eradikation von Helicobacter pylori durch Rauchen, aber nichtdurch eine Omeprazol Vorbehandlung. Schweiz Med Wochenschr 1994; 124: 1398-404
19. Labenz J, Rühl GH, Bertrams J, et al. Medium or high dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol 1994; 89: 726-30
20. DeBartolo M, Reitmayer R, Olson C, et al. Effect of smoking on H. pylori eradication and duodenal ulcer recurrence in patients receiving dual therapy with clarithromycin in combination with omeprazole [abstract]. Gut 1995; 37 Suppl. 1: 337
21. O'Connor HJ, Kanduru C, Bhutta AS, et al. Effect of Helicobacter pylori eradication on peptic ulcer healing. Postgrad Med J 1995; 71: 90-3
22. Lambert JR, Arena G. Mucosal antibiotic levels. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht: Kluwer, 1994: 538-49
23. Graham DY, Borsch GM. The who's and when's of therapy for Helicobacter pylori. Am J Gastroenterol 1990; 85: 1552-5
24. Koo MWL, Ogle CW, Cho CH. Effects of verapamil, carbenoxolone and N-acetyl-cysteine on gastric wall mucus and ulceration in stressed rats. Pharmacology 1986; 36: 326-34
25. Zala G, Flury R, Wüst J, et al. Omeprazole/amoxicillin: verbesserte Eradikationvon Helicobacter pylori bei Rauchern durch N-Acetylcystein. Schweiz Med Wochenschr 1994; 124: 1391-7
26. Brogden R, Pinder R, Sawyer P, et al. Tripotassium dicitrato bismuthate: a report of its pharmacological properties and therapeutic efficacy in peptic ulcer. Drugs 1976; 12: 401-11
27. Bianchi Porro G, Lazzaroni M, Cortvriendt WRE. Colloidal bismuth subcitrate in duodenal ulcer disease. Digestion 1987; 37 Suppl. 22: 47-52
28. Lambert JR. Pharmacology of bismuth containing compounds. Rev Infect Dis 1991; 13 Suppl. 8: 691-5
29. Collins R, Coghlan JG, O'Morain C. Helicobacter pylori and ulcer treatment. In: Rathbone BJ, Heatley RV, editors. Helicobacter pylori and gastroduodenal disease. 2nd ed. London: Blackwell, 1992: 244-58
30. Wagstaff AJ, Benfield P, Monk JP. Colloidal bismuth subcitrate: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic use in peptic ulcer disease. Drugs 1988; 36: 132-57
31. Bader JP. The safety profile of De-Nol. Digestion 1987; 37 Suppl. 2: 53-9
32. Malfertheiner P, Nilius M. Bismuth preparations. In: Helicobacter pylori: biology and clinical practice. Goodwin CS, Worsiey BW, editors. Boca Raton: CRC Press Inc., 1993: 351-64
33. Froomes PRA, Wan AT, Keech AC, et al. Absorption and elimination of bismuth from oral doses of tripotassium-dicitratobismuthate. Eur J Clin Pharmacol 1989; 37: 533-36
34. Nwokolo CU, Gavey CJ, Smith JTL, et al. The absorption of bismuth from oral doses of tripotassium dicitrato bismuthate. Aliment Pharmacol Ther 1989; 3: 29-39
35. Hespe W, Staal HJM, Hall DWR. Bismuth absorption from the colloidal subcitrate [letter]. Lancet 1988; II: 1258
36. Lambert JR, Way DJ, King RG, et al. Bismuth pharmacokinetics in the human gastric mucosa [abstract]. Gastroenterology 1988; 94: A248
37. Gavey CJ, Szeto ML, Nwokwolo CU, et al. Bismuth accumulates in the body during treatment with tripotassium-dicitrato-bismuthate. Aliment Pharmacol Ther 1989; 3: 21-8
38. Dekker W, Dal Monte PR, Bianchi Porro G, et al. An international multi-clinic study comparing the therapeutic efficacy of colloidal bismuth subcitrate coated tablets with chewing tablets in the treatment of duodenal ulceration. Scand J Gastroenterol 1986; 21 Suppl. 122: 46-50
39. Lee SP. Studies on the absorption and excretion of tripotassium dicitrato bismuthate in man. Res Commun Chem Pathol Pharmacol 1981; 43: 359-64
40. Nwokolo CU, Lewin JF, Hudson M, et al. Transmucosal penetration of bismuth particles in the human stomach. Gastroenterology 1992; 102: 163-7
41. Bes A, Caussanel JP, Geraud G, et al. Encephalopathie toxique par les sels de bismuth. Rev Med Toulouse 1976; 12: 801-13
42. Playford RJ, Matthews CH, Campbell MJ, et al. Bismuth-induced encephalopathy caused by tripotassium dicitrato bismuthate in a patient with chronic renal failure. Gut 1990; 31: 359-60
43. Caron F, Rouveix B. Le renouveau du bismuth dans l'infection gastroduodenale a Helicobacter pylori. Therapie 1991; 46: 393-8
44. Lee SP. A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid. Scand J Gastroenterol 1982; 17 Suppl. 80: 17-21
45. Konturek SJ, Bilski J, Kwiecien N, et al. De-Nol stimulates gastric and duodenal alkaline secretion through a prostaglandin dependant mechanism. Gut 1987; 28: 1557-63
46. Beil W, Bierbaum S, Sewing KF. Studies on the mechanism of action of colloidal bismuth subcitrate. I. Interaction with sulphydryls. Pharmacology 1993; 47: 135-40
47. Ottlecz A, Romero JJ, Hazell SL, et al. Phospholipase activity of Helicobacier pylori and its inhibition by bismuth salts. Dig Dis Sci 1993; 38: 2071-80
48. Roine RP, Salmela KS, Hook-Nikanne J, et al. Colloidal bismuth subcitrate and omeprazole inhibit alcohol dehydrogenase mediated acetaldehyde production by Helicobacter pylori. Life Sci 1992; 51: 195-200
49. Van der Voort LHM, Van den Bos AP, Kamsteeg H. In vitro bactericidal effects of CBS on Helicobacter pylori [abstract]. Rev Esp Enferm Dig 1990; 78 Suppl. 1: A103
50. Huesca M, Gold B, Sherman P, et al. Colloidal bismuth subcitrate (CBS) blocks Helicobacter pylori adhesion to glycero-lipid receptors [abstract]. Gastroenterology 1992; 102: A639
51. Grayson ML, Liopoulos E, Ferraro MJ. Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents. Eur J Clin Microbial Infect Dis 1989; 8: 888-9
52. Goodwin CS, McNulty CAM. Bacteriological and pharmacological basis for the treatment of Helicobacter pylori infection. In: Rathbone BJ, Heatley RV, editors. Helicobacter pylori and gastroduodenal disease. 2nd ed. London: Blackwell 1992: 224-31
53. Coghlan JD, Gilligan D, Humphreys H, et al. Efficacy of different dosage regimens in duodenal ulcer healing and eradication of Campylobacter pylori [abstract]. Gut 1987; 28: A1409
54. Lambert JR, Lin SK, Shembri M, et al. Comparison of different preparations of Denol in healing of duodenal ulcer and Helicobacter pylori eradication [abstract]. Hellen J Gastroenterol 1992; 5: 190
55. Chiba N, Rao BV, Rademaker JW, et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-27
56. Goodwin CS, Marshall BJ, Blincow ED. Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies. J Clin Pathol 1988; 41: 207-10
57. Bell GD, Powell K, Burridge SM, et al. Does a previous course of tripotassium dicitrato bismuthate affect the subsequent chances of successful Helicobater pylori eradication? Aliment Pharmacol Ther 1992; 6: 327-33
58. Maton PN, Omeprazole. New Engl J Med 1991; 324: 965-75
59. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid related disorders. Drugs 1992; 44: 225-50
60. Creutzfeldt W. Risk-benefit assessment of omeprazole in the treatment of gastrointestinal disorders. Drug Saf 1994; 10: 66-82
61. Wilde MI, McTavish D. Omeprazole: an update of its pharmacology and therapeutic use in acid related disorders. Drugs 1994; 48: 91-132
62. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid related disorders. Drugs 1994; 48: 404-30
63. Burette A, Glupczynski Y, Deprez C, et al. Omeprazole alone or in combination with clarithromycin for eradication of Helicobacter pylori: results of a randomized double-blind, controlled study [abstract]. Gastroenterology 1993; 104: 49
64. Suerbaum S, Leying H, Klemm K, et al. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991; 10: 92-3
65. Iwahi T, Satoh H, Nakao M, et al. Lansoprazole, a novel benzimidazole proton pump inhibitor and its related compounds have selective activity against Helicobacter pylori. Antimicrob Agents Chemother 1991; 35: 490-6
66. Unge P, Gad A, Gnarpe H, et al. Does omeprazole improve antimicrobial therapy directed towards gastric Campylobacter pylori in patients with antral gastritis? A pilot study. Scand J Gastroenterol 1989; 24 Suppl. 167: 49-54
67. Hui WM, Lam SK, Ho J, et al. Effect of omeprazole on duodenal ulcer-associated antral gastritis and Helicobacter pylori. Dig Dis Sci 1991; 36: 577-82
68. Rauws EA, Langenberg W, Bosma A, et al. Lack of eradication of Helicobacter pylori after omeprazole [letter]. Lancet 1991; 337: 1093
69. Weil J, Bell GD, Powell K, et al. Omeprazole and Helicobacter pylori temporary suppression rather than true eradication. Aliment Pharmacol Ther 1991; 5: 309-13
70. Louw JA, Zak J, Jaskiewicz K, et al. Omeprazole may clear but not eradicate H. pylori. Eur J Gastroenterol Hepatol 1992; 4: 481-5
71. Sherman P, Shames B, Loo V, et al. Omeprazole therapy for Helicobacter pylori infection. Scand J Gastroenterol 1992; 27: 1018-22
72. Vigneri S, Termini R, Scialabba A et al. Omeprazole therapy modifies the gastric localization of Helicobacter pylori. Am J Gastroenterol 1991; 86: 1276-7
73. Logan RPH, Walker MM, Misiewicz JJ, et al. Changes in the intragastric distribution of Helicobacter pylori during treatment with omeprazole. Gut 1995; 36: 12-6
74. Bugnoli M, Bayeli PF, Rappuoli R, et al. Inhibition of Helicobacter pylori urease by omeprazole. Eur J Gastroenterol Hepatol 1993; 5: 683-5
75. Nagata K, Satoh H, Iwahi T, et al. Potent inhibitory action of gastric pump inhibitor lansoprazole against urease activity of Helicobacter pylori: unique action selective for H. pylori cells. Antimicroh Agents Chemother 1993; 37: 769-74
76. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol 1994; 29 Suppl. 201: 16-23
77. McGowan CC, Cover TL, Blaser MJ. The proton pump inhibitor omeprazole inhibits acid survival of Helicobacter pylori by a urease-independent mechanism. Gastroenterology 1994; 107: 1573-8
78. Suerbaum S, Leying H, Klemm K, et al. Antibacterial activity of pantoprazole and omeprazole against Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1991; 10: 92-3
79. Ge Z, Hiratsuka K, Taylor DE. Nucleotide sequence and mutational analysis indicate that two Helicobacter pylori genes encode a P-type ATPase and a cation binding protein associated with copper transport. Mol Microbiol 1995; 15: 97-106
80. Wandall JH. Effects of omeprazole on neutrophil chemotaxis, super oxide production, degranulation and translocation of cytochrome b-245. Gut 1992; 33: 617-21
81. Treiber G, Walker S, Klotz U. Omeprazole induced increase in the absorption of bismuth from tripotassium dicitrato bismuthate. Clin Pharmacol Ther 1994; 55: 486-91
82. Forne M, Viver JM, Espinos JC, et al. Impact of colloidal bismuth subcitrate in the eradication rates of Helicobacter pylori-associated duodenal ulcer using a short treatment regime with omeprazole and clarithromycin. Am J Gastroenterol 1995; 90: 718-21
83. Grant SM, Langtry HD, Brogden RN. Ranitidine: an updated review. Drugs 1989; 37: 801-70
84. Feldman M, Burton ME. Histamine2-receptor antagonists standard therapy for acid-peptic diseases. N Engl J Med 1990; 323 (2Pt 1): 1672-80
85. Feldman M, Burton ME. Histamine2-receptor antagonists standard therapy for acid-peptic. N Engl J Med 1990; 323: (2 Pt 2): 1749-55
86. Holt S. Over the counter histamine2-receptor antagonists: how will they affect the treatment of acid related diseases? Drugs 1994; 47: 1-11
87. Martin DF, Hollanders D, May SJ, et al. Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate. Lancet 1981; 1: 7-10
88. Bianchi Porro G, Barbara L, Cheli R, et al. Comparison of tripotassium dicitrato bismuthate (TDB) tablets and ranitidine in healing and relapse of duodenal ulcer [abstract]. Gut 1984; 25: A565
89. Lee SP, Samloff IM, Hardman M. Comparison of tripotassium dicitrato bismuthate tablets with ranitidine in healing and relapse of duodenal ulcers. Lancet 1985; 1: 1299-302
90. Hamilton I, O'Connor HJ, Wood NC, et al. Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets and cimetidine. Gut 1986; 27: 106-10
91. Miller JP, Faragher EB. Relapse of duodenal ulcer: does it matter which drug is used in initial treatment? BMJ 1986; 293: 1117-8
92. Fullman H, Van Deventer G, Schneidman D, et al. Healed duodenal ulcers are histologically ill [abstract]. Gastroenterology 1985; 88: A1390
93. Goodwin CS, Blake P, Blincow E. The minimum inhibitory bactericidal concentrations of antibiotics and anti-ulcer agents against Campylobacter pyloridis. J Antimicrobiol Chemother 1986; 17: 309-14
94. Andreasen JJ, Andersen LP. In vitro susceptibility of Campylobacter pyloridis to cimetidine, sucralfate and sixteen antibiotics. Acta Pathol Immun Scand 1987; 95: 147-9
95. Andersen LP. Cytoprotective agents and C. pylori associated acid peptic diseases. Scand J Gastroenterol 1988; 23 Suppl. 142: 110-3
96. Bayerdörffer E, Otlenjann R. The role of antibiotics in Campylobacter pylori associated peptic ulcer disease. Scand J Gastroenterol 1988; 23 Suppl. 142: 93-100
97. Shungu KL, Nalin DR, Gilman RH, et al. Comparative susceptibilities of Campylobacter pylori to norfloxacin and other agents. Antimicrob Agents Chemother 1987; 31: 949-50
98. Blanco M, Pajares JM, Jimenez ML, et al. Effect of acid inhibition on Campylobacter pylori. Scand J Gastroenterol 1988; 23 Suppl. 142: 107-9
99. Ho J, Hui WM, NG I, et al. Natural history of Campylobacter pylori in duodenal ulceration treated with an H2-antagonist. Aliment Pharmacol Ther 1989; 3: 315-20
100. Hentschel E, Brandstätter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12
101. DeBoer WA, Driessen WM, Potters HVPJ, et al. Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 1993-97
102. Adamek RJ, Opferkuch W, Wegener M. Modified short-term triple therapy: ranitidine, clarithromycin and metronidazole for cure of Helicobacter pylori infection. Am J Gastroenterol 1995; 90: 168-9
103. Spadaccini A, Masciulli V, DeFanis G, et al. Ranitidine vs omeprazole: short term triple therapy in patients with Helicobacter pylori positive duodenal ulcer [abstract]. Gut 1995; 33 Suppl 2: A204, 1734
104. Stables R, Campbell CJ, Clayton NM, et al. Gastric anti-secretory, mucosal protective, anti-pepsin and anti-Helicobacter properties of ranitidine bismuth citrate. Aliment Pharmacol Ther 1993; 7: 237-46
105. Peterson WL, Sontag SJ, Ciociola AA, et al. Ranitidine bismuth citrate plus clarithromycin is effective in the eradication of Helicobacter pylori and prevention of duodenal ulcer relapse [abstract]. Gut 1995; 37 Suppl. 1: 19
106. Bardhan KD, Dallaire C, Eisold H, et al. The treatment of duodenal ulcer with GR122311X (ranitidine bismuth citrate) and clarithromycin [abstract]. Gut 1995; 37 Suppl. 1: 20
107. Butruk E, Ching CK, Schütze K, et al. GR122311X (ranitidine bismuth citrate) with amoxycillin for the treatment of duodenal ulcer [abstract]. Gastroenterology 1995; 108: A64
108. Webb DD, Ciociola AA, Perschy TB, et al. Effect of administration of ranitidine bismuth citrate with food on the suppression and eradication of Helicobacter pylori in infected volunteers. Am J Gastroenterol 1995; 90: 1273-7
109. Nwokolo CU, Prewett EJ, Sawyer AM, et al. Bismuth pharmacokinetics following dosing with three bismuth-containing ulcer healing compounds: the effect of H2-blockade [abstract]. Gastroenterology 1990; 98 Suppl.: A97
110. McNulty CAM, Dent JC, Wise R. Susceptibility of clinical isolates of Campylobacter pylori to 11 antimicrobial agents. Antimicrob Agents Chemother 1985; 28: 837-8
111. McNulty CAM, Dent JC. Susceptibility of Campylobacter pylori to twenty-one antimicrobial agents. Eur J Clin Microbiol Infect Dis 1988; 7: 566-9
112. Graham DY, Operkun AR, Klein PD. Clarithromycin for the eradication of Helicobacter pylori. J. Clin Gastroenterol 1993; 16: 292-4
113. Peterson WL, Graham DY, Marshall B, et al. Clarithromycin as monotherapy for eradication of Helicobacter pylori: a randomized, double-blind trial. Am J Gastroenterol 1993; 88: 1860-64
114. Rauws EAJ, Langenberg W, Houthoff HJ, et al. Campylobacter pyloridis associated chronic active antral gastritis: a prospective study of its prevalence and the effects of antibacterial and antiulcer treatment. Gastroenterology 1988; 94: 33-40
115. Tytgat GNJ, Rauws EAJ, Lungenberg W, et al. Long-term follow-up of C pyloridis gastritis after treatment with colloidal bismuth subnitrate and/or amoxicillin [abstract]. Gastroenterology 1988; 94: A469
116. Gilman R, Leon-Barua R, Ramirez-Ramos A, et al. Efficacy of nitrofurantoin in the treatment of antral gastritis associated with Campylobacter pyloridis [abstract]. Gastroenterology 1986; 92: A1405
117. Unge P, Gnarpe H, Blomquits C. Campylobacter pylori: Swedish experiences. Scand J Gastroenterol 1989; 24 Suppl. 157: 12-5
118. Westblom TU, Madan E, Subik MA, et al. Double-blind randomized trial of bismuth subsalicylate and clindamycin for treatment of Helicobacter pylori infection. Scand J Gastroenterol 1992; 27: 249-52
119. McNulty CAM, Gearty JC, Crump B, et al. Campylobacter pyloridis and associated gastritis: investigator-blind, placebo-controlled trial of bismuth salicylate and erythromycin ethylsuccinate. BMJ 1986; 293: 645-9
120. Glupczynski Y, Labbe M, Burette A, et al. Treatment failure of ofloxacin in Campylobacter pylori infection [letter]. Lancet 1987; 1: 1096
121. Stone JW, Wise R, Donovan IA, et al. Failure of ciprofloxacin to eradicate Campylobacter pylori from the stomach. J Antimicrob Chemother 1988; 22: 92-3
122. McNulty CAM, Dent JC, Ford GA, et al. Inhibitory antimicrobial concentrations against Campylobacter pylori in gastric mucosa. J Antimicrob Chemother 1988; 22: 729-38
123. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28 Suppl. 196: 12-16
124. Tytgat GNJ. Review article: treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359-68
125. Cooreman M, Krausgrill P, Schumacher B, et al. Amoxycillin concentration in antrum, corpus and fundus of the stomach after single oral application. Klin Wochenschr 1989; 67 Suppl. XVIII: 12-13
126. Lambert JR, Loncar B, Schembri MA, et al. Luminal amoxycillin determines gastric mucosal concentrations [abstract]. Gastroenterology 1991; 100: A104
127. Hollingworth K, Goldie J, Siletti CF, et al. Gastric secretion of antibiotics used for Campylobacter pyloridis [abstract]. Gut 1987; 28: A1409
128. Veldhuyzen van Zanten SJO, Goldie J, Hollingworth J, et al. Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. J Clin Pathol 1992; 45: 225-7
129. Adamek RJ, Wegener M, Opferkuch W, et al. Successful Helicobacter pylori eradication: a systemic effect of antibiotics? Am J Gastroenterol 1993; 88: 792-3
130. Adamek RJ, Freitag M, Opferkuch W, et al. Intravenous omeprazole/amoxicillin and omeprazole pretreatment in Helicobacter pylori positive acute peptic ulcer bleeding. Scand J Gastroenterol 1994; 29: 880-3
131. Adamek RJ, Wegener M, Labenz J, et al. Medium term results of oral and intravenous omeprazole/amoxicillin in Helicobacter pylori eradication therapy. Am J Gastroenterol 1994; 89: 39-42
132. Atherton JC, Hudson N, Kirk GE, et al. Amoxycillin capsules with omeprazole for the eradication of Helicobacter pylori assessment of the importance of antibiotic dose timing in relation to meals. Aliment Pharmacol Ther 1994; 8: 495-8
133. Kerr JR. Penicillin allergy: a study of incidence as reported by patients. Br J Clin Pract 1994; 48: 5-7
134. Fenlon MR, McCartan BE. Medical status of patients attending a primary care dental practice in Ireland. J Ir Dent Assoc 1991; 37: 75-7
135. Sue MA, Noritake DT, Klaustermeyer WB. Penicillin anaphylaxis: fatality in elderly patients without a history of penicillin allergy. Am J Emerg Med 1988; 6: 456-8
136. Miles AM, Bain B. Penicillin anaphylaxis: a review of sensitization, treatment and prevention. J Assoc Acad Minor Phys 1992; 3: 50-6
137. Bartlett JG. Antimicrobial agents implicated in Clostridium difficile toxin associated diarrhoea or colitis. Johns Hopkins Med J 1981; 149: 6-10
138. Carbon C, Richard A, Bons B. Les colites pseudo-membraneuses associees a l'antibiotherapie: resultats d'une enquete aupres de 900 gastroenterologues. Therapie 1994; 49: 325-31
139. Awad RW, Ward KL, Hawker PC. Fulminant pseudomembranous colitis (PMC) following triple therapy for Helicobacter pylori [abstract]. J R Coll Surg Edinb 1994; 39: 319
140. Famerée D, Ramdani B, Lamy V. Assessment of Helicobacter pylori's sensitivity to tinidazole, amoxycillin and tetracycline among 472 patients. Third Workshop of the Helicobacter pylori study group [abstract]. Rev EspEnf Dig 1990; 78: P219
141. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob Agents Chemother 1990; 34: 1637-41
142. Tucci A, Varoli O, Corinaldesi R, et al. Evaluation of Helicobacter pylori sensitivity to amoxycillin and metronidazole in dyspeptic patients. Ital J Gastroenterol 1993; 25: 65-7
143. Sieber CC, Frei R, Beglinger C, et al. Resistenz von Helicobacter pylori gegen Metronidazole in der Schweiz: Implikationenfür die Eradikationstherapie. Schweiz Med Wochenschr 1994; 124: 1381-4
144. Boixeda D, De Rafael L, Canton R, et al. Galenical formulations of amoxicillin/clavulanate and eradication of Helicobacter pylori in peptic ulcer patients: preliminary report. Eur J Gastroenterol Hepatol 1993; 5: 283-5
145. Larrey D, Vial T, Micaleff A, et al. Hepatitis associated with amoxycillin-clavulanic acid combination: report of 15 cases. Gut 1992; 33: 368-71
146. Hardy DJ, Hanson CW, Hensey DM, et al. Susceptibility of Campylobacter pylori to macrolides and fluoroquinolones. J Antimicrob Chemother 1988; 22: 631-36
147. Glupczynski Y, Burette A. Failure of azythromycin to eradicate Campylobacter pylori from the stomach because of acquired resistance during treatment [letter]. Am J Gastroenterol 1990; 85: 98-9
148. Peters DH, Clissold SP. Clarithromycin: a review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential. Drugs 1992; 44: 117-64
149. Chang K, Wyle F, Skankey J. et al. Clarithromycin achieves highest gastric mucosa tissue level among anti-Helicobacter pylori antibiotics [abstract]. Gastroenterology 1993; 104: A680
150. Malanoski GJ, Eliopoulos GM, Ferraro MJ, et al. Effect of pH variation on the susceptibility of Helicobacter pylori to three macrolide antimicrobial agents and temafloxacin. Eur J Clin Microbiol Infect Dis 1993; 12: 131-3
151. Kakegawa T, Hirose S. Mode of inhibition of protein synthesis by metabolites of clarithromycin. Chemotherapy 1990; 38: 317-23
152. Pichotta P, Gupta S, Prokocimer P, et al. The overall safety of oral clarithromycin in comparative clinical studies. 30th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. 1990 Oct; Atlanta, Georgia.
153. Anderson G, Esmonde TS, Coles S, et al. A comparative safety and efficacy study of clarithromycin and erythromycin stearate in community acquired pneumonia. J Antimicrob Chemother 1991; 27: Suppl. A: 117-24
154. Braegger C, Nadal D. Clarithromycin and pseudomembranous colitis. Lancet 1994; 343: 241-2
155. Teare JP, Booth JCL, Brown JL, et al. Pseudomembranous colitis following clarithromycin therapy. Eur J Gastroenterol Hepatol 1995; 7: 275-7
156. Al-Assi, Genta RM, Kartrunen TJ, et al. Clarithromycin-amoxycillin therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 453-6
157. Logan RP, Gummett PA, Schaufelberger HD, et al. Eradication of Helicobacter pylori with clarithromycin and omeprazole. Gut 1994; 35: 323-6
158. Tytgat GNJ, Noach LA. H. pylori eradication. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht, Kluwer, 1994: 550-69
159. Lambert HP, O'Grady FW. Antibiotics and chemotherapy. 6th ed. Edinburgh. Churchill Livingstone, 1992
160. Mgraud F. H. pylori resistance to antibiotics. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht: Kluwer, 1994: 570-83
161. Glupczynski Y. Result of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-81
162. De Cross AJ, Marshall BJ, McCallum RW, et al. Metronidazole susceptibility testing for Helicobacter pylori: comparison of disk, broth and agar dilution methods and their clinical relevance. J Clin Microbiol 1993; 31: 1971-4
163. Glupczynski Y, Burette A, De Koster E, et al. Metronidazole resistance in Helicobacter pylori. Lancet 1990; 335: 976-7
164. Banatvala N, Davies GR, Abdi Y, et al. High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease. Gut 1994; 35: 1562-6
165. Willemin B, Camou C, Rochereau A, et al. Helicobacter pylori in Africa. Is there an African enigma? Acta Gastroenterol Belg 1994; 56 Suppl.: 93
166. Andrzejewska E, Jenek J, Klincewicz H, et al. Occurrence of Helicobacter pylori strains resistant to metronidazole [in Polish]. Med Dosw Mikrobiol 1994; 46: 169-73
167. Witteman EM, Hopman WPM, Becx MCJ, et al. Short report: smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori-related gastritis. Aliment Pharmacol Ther 1993; 7: 683-7
168. Cederbrant G, Kahlmeter G, Ljungh A. Proposed mechanism for metronidazole resistance in Helicobacter pylori. J Antimicrob Chemother 1992; 29: 115-20
169. VanZweet AA, Thijs JC, de Graaf B. Explanations for high rates of eradication with triple therapy using metronidazole-resistant Helicobacter pylori strains. Antimicrob Agents Chemother 1995; 39: 250-2
170. Rautelin H, Seppälä K, Renkonen OV, et al. Role of metronidazole resistance in therapy of Helicobacter pylori infections. Antimicrob Agents Chemother 1992; 36: 163-66
171. Noach LA, Langenberg WL, Bertola MA, et al. Impact of metronidazole resistance on the eradication of Helicobacter pylori. Scand J Infect Dis 1994; 26: 321-7
172. Learned Coughlin S. Peripheral neuropathy induced by metronidazole [letter]. Ann Pharmacother 1994; 28: 536
173. Simon C, Stille W. Antibiotika-Therapie in Klinik and Praxis, 8th edition. Stuttgart, Schattauer, 1993: 252-8
174. Westblom TU, Gudipati S, Midkif BR. In vitro susceptibility of Helicobacter pylori to three new oral cephalosporins Cefodoxime, Cefibuten and Cefixime. Eur J Clin Microbiol Infect Dis 1990; 9: 691-2
175. Loo VG, Sherman P, Mallow AG. Helicobacter pylori infection in a pediatric population: in vitro susceptibilities to omeprazole and eight antimicrobial agents. Antimicrob Agents Chemother 1992; 36: 1133-5
176. Battaglia G, Di Mario F, Ferrana M, et al. Cefixime for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 33-6
177. Tytgat GNJ, Axon ATR, Dixon ME, et al. Helicobacter pylori: causal agent in peptic ulcer disease? Working party report of the World Congresses of Gastroenterology 1990; Melbourne: Blackwell Scientific, 1990: 36-45
178. Penston JG. Review article: Helicobacter pylori eradication - understandable caution but no excuse for inertia. Aliment Pharmacol Ther 1994; 8: 369-89
179. Patchett S, Beattie S, Keane C, et al. Short report: short-term triple therapy for H. pylori associated duodenal ulcer disease. Aliment Pharmacol Ther 1992; 6: 113-7
180. Börsch G, Mai U, Opferkuch W. Short- and medium-term results of oral triple therapy to eradicate C. pylori [abstract]. Gastroenterology 1989; 96: A53
181. Hosking SW, Ling TKW, Chung SCS, et al. Duodenal ulcer healing by eradication of Helicobacter pylori without antiacid treatment: randomised controlled trial. Lancet 1994; 343: 508-10
182. Sung JJY, Chung S, Ling TKW, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332: 139-42
183. Lambert JR, Lin SK, Shembri M, et al. Helicobacter pylori therapy. Randomized study of denol/antibiotic combinations. Rev Esp Enferm Dig 1990; 78 Suppl. 1: 115-116
184. Borody TJ, Brandl S, Andrews P, et al. High efficacy, low dose triple therapy for Helicobacter pylori [abstract]. Gastroenterology 1992; 102: Suppl. 1: A44
185. Logan RPH, Gummett PA, Misiewicz JJ, et al. One week eradication regimen for Helicobacter pylori. Lancet 1991; 338: 1249-52
186. Lynch DAF, Sobala GM, Gallacher B, et al. Effectiveness of a five times daily triple therapy regimen against Helicobacter pylori. J Antimicrob Chemother 1994; 33: 877-9
187. Borody TJ, Brandi S, Andrews P, et al. Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori. Am J Gastroenterol 1994; 89: 33-8
188. Bell GD, Powell K, Burridge SM, et al. Experience with triple anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-35
189. Thijs JC, Van Zweel AA, Oey HB. Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori. Scand J Gastroenterol 1993; 28: 934-38
190. Rautelin H, Kosunen TU, Seppälä K, et al. Eradicating Helicobacter pylori. Lancet 1992; 339: 54-5
191. Xia H, Daw MA, Sant S, et al. Clinical efficacy of triple therapy in Helicobacter pylori associated duodenal ulcer. Eur J Gastroenterol Hepatol 1993; 5: 141-4
192. Zweet AA, Thijs JC, Oom JAJ, et al. Failure to eradicate Helicobacter pylori in patients with metronidazole resistant strains. Eur J Gastroenterol Hepatol 1993; 5: 185-6
193. Bell GD, Powell K, Burridge SM, et al. Experience with triple anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther 1992; 6: 427-35
194. Thijs JC, Van Zwet AA, Moolenar W, et al. Clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection. Aliment Pharmacol Ther 1994; 8: 131-4
195. Al Assi MT, Ramirez FC, Lew GM, et al. Clarithromycin. tetracyclin and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection. Am J Gastroenterol 1994; 89: 1203-5
196. Borody TJ, Andrews P, Fracchia G, et al. omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. Gut 1995; 37: 477-81
197. DeBoer W, Driessen W, Jansz A, et al. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection Lancet 1995; 345: 817-20
198. DeBoer W, Driessen W, Tytgat GNJ. Only four days of quadruple therapy can effectively cure Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 633-8
199. Paulsen O, Höglund P, Walder M. No effect of omeprazole-induced hypoacidity on the bioavailability of amoxicillin or bacampicillin. Scand J Infect Dis 1989; 21: 219-23
200. Pommerien W, Braun M, Idström JP, et al. No interaction between omeprazole and amoxicillin during combination therapy in Helicobacter pylori positive healthy subjects [abstract]. Gastroenterology 1995; 108: A194
201. Bayerdörffer E, Mannes GA, Sommer A, et al. High dose omeprazole treatment combined with amoxicillin eradicates Helicobacter pylori. Eur J Gastroent Hepatol 1992; 4: 697-702
202. Bayerdörffer E, Mannes GA, Sommer A, et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol 1993; 28 Suppl. 169: 19-25
203. Bayerdörffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108: 1412-7
204. Labenz J, Gyenes E, Rühl GH, et al. Omeprazole plus amoxycillin: efficacy of various treatment regimes to eradicate Helicobacter pylori. Am J Gastroenterol 1993; 88: 491-5
205. Labenz J, Gyenes E, Rühl GH, et al. Amoxycillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut 1993; 34: 1167-70
206. Labenz J, Rühl GH, Bertrams J, et al. Medium and high dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci 1994; 39: 1483-7
207. Mannes GA, Bayerdörffer E, Hele C, et al. An increasing dose of omeprazole combined with amoxicillin increases the eradication rate of Helicobacter pylori [abstract]. Gastroenterology. 1993; 104: Suppl. A140
208. Goh KL, Peh SC, Parasakthi N, et al. Omeprazole 40 mg om combined with amoxycillin alone or with amoxicillin and metronidazole in the eradication of Helicobacter pylori. Am J Gastroenterol 1994; 89: 1789-92
209. Bell GD, Powell K, Weil J, et al. Experience with omeprazole in combination with either amoxycillin or colloidal bismuth subcitrate in patients with metronidazole resistant Helicobacter pylori. Eur J Gastroenterol Hepatol 1991; 3: 923-6
210. Bell GD, Powell KU, Bunidger SM, et al. Short report: Omeprazole + antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori. Aliment Pharmacol Ther 1992; 6: 751-8
211. Collins R, Beattie S, O'Morain C. High dose omeprazole plus amoxycillin in the treatment of acute duodenal ulcer [abstract]. Ir J Med Sci 1992; 161 Suppl. 10: 96
212. De Koster E, Nyst JF, Deprez C, et al. Helicobacter pylori treatment: disappointing results with amoxicillin plus omeprazole [abstract]. Gastroenterology 1992; 87: A58
213. Lamouliatte H, DeMascarel A, Megraud F, et al. Omeprazole improves antimicrobial therapy directed towards Helicobacter pylori associated chronic gastritis [abstract]. Gastroenterology 1990; 98: A75
214. Pommerien W, Schultze V, Lembcke B, et al. Dose response of twice daily dosing of omeprazole combined with amoxicillin on H. pylori eradication in duodenal ulcer patients [abstract]. Gastroenterology 1995; 108: A193
215. Erdag S, Bojko JB, Burlage M et al. Optimal compliance eliminates differences in eradication rates between 2 week dual and 1 week triple therapy for Helicobacter pylori gastritis [abstract]. Gastroenterology 1996; 110 Suppl. 1.: A103
216. Miehlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxicillin improves the cure of Helicobacter pylori infection [abstract]. Gastroenterology 1995; 108: A167
217. Gustavson LE, Kaiser JF, Mukherjee DX, et al. Evaluation of pharmakokinetic drug interactions between clarithromycin and omeprazole [abstract]. Am J Gastroenterol 1994; 89: 1373
218. O'Morain C, Dettmer A, Rambow A, et al. and the Clarithromycin European H. pylori Study Group. Dual therapy with clarithromycin and omeprazole for the treatment of active duodenal ulcers [abstract]. Am J Gastroenterol 1994; 89: A1384
219. Labenz J, Stolte M, Domian C, et al. High dose omeprazole plus amoxicillin or clarithromycin cures Helicobacter pylori infection in duodenal ulcer disease. Digestion 1995; 56: 14-20
220. Edmonds A, Reitmayer R, DeBartolo M, et al. Effect of smoking on H. pylori eradication in patients receiving dual therapy with clarithromycin and omeprazole [abstract]. Am J Gastroenterol 1994; 89: 1636
221. Cayla R, Lamouliatte HC, Brugman M, et al. Pre-treatment resistance of Helicobacter pylori to metronidazole and macrolides [abstract]. Acta Gastroenterol Belg 1993; 56 Suppl.: 65
222. Metz DC, Getz HD. Helicobacter pylori gastritis therapy with omeprazole and clarithromycin increases serum carbamazepine levels. Dig Dis Sci 1995; 40: 912-5
223. Harris AW, Gummett PA, Logan RP, et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. Aliment Pharmacol Ther 1995; 9: 201-4
224. Cayla R, Zerbib F, de Mascarel A, et al. High dose of lansoprazole in combination with amoxycillin and clarithromycin twice daily for H. pylori eradication: results of a pilot study [abstract]. Am J Gastroenterol 1994; 94: A1367
225. Bell GD, Powell KU, Burridge SM, et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med 1993; 86: 743-50
226. Bell GD, Powell KU, Burridge SM, et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 41-6
227. Bazzoli F, Zagari RM, Fossi S, et al. Efficacy and tolerability of a short-term, low-dose triple therapy for eradication of Helicobacter pylori [abstract]. Gastroenterology 1993; 104: A140
228. Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-7
229. Bazzoli F, Zagari RM, Fossi S, et al. Effect of omeprazole, clarithromycin and tinidazole on the eradication of Helicobacter pylori and healing of gastric ulcer [abstract]. Gastroenterology 1996; 110 Suppl. 1: A60
230. Moayyedi P, Axon ATR. Efficacy of a new one week triple therapy regime in eradicating Helicobacter pylori [abstract]. Gut 1994; 35 Suppl. 2: F248
231. Jaup BH, Norrby A. Low-dose, short term triple therapy for cure of Helicobacter pylori infection and healing of peptic ulcers. Am J Gastroenterol 1995; 90: 943-5
232. Labenz J, Stolte M, Rühl GH, et al. One week, low-dose triple therapy for the cure of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1994; 7: 9-11
233. Moayyedi P, Tompkins DS, Axon ATR. Determination of the optimum dose of omeprazole in a new triple therapy regimen for eradicating Helicobacter pylori [abstract]. Gut 1994; 35: Suppl. 5: W63
234. Yousfi MM, El Zimaity HM, Al Assi MT, et al. Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 209-12
235. Peitz U, Nusch A, Tillenburg B, et al. Frequent metronidazole resistance without significant impact on the high cure rate of Helicobacter pylori cure rate by triple therapy with omeprazole, metronidazole and clarithromycin [abstract]. Gastroenterology 1996; 110 Suppl. 1: A226
236. Pryce DI, Harris AW, Gabe SM et al. One week of lansoprazole, clarithromycin and metronidazole eradicates Helicobacter pylori [abstract]. Gastroenterology 1996; 110 Suppl. 1: A235
237. Adamek RJ, Szymanski C, Pfaffenbach B, et al. Short term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection. Dtsch Med Wochenschr 1995; 120: 358-60
238. Cayla R, Zerbib F, de Mascarel A, et al. Dual therapy with high dose of omeprazole versus triple therapy using omeprazole in combination with two antibiotics for H. pylori eradication: results of a randomised controlled trial among 100 patients [abstract]. Am J Gastroenterol 1994; 94: 1366
239. Cayla R, de Mascarel F, Joubert-Collin M, et al. High dose of lansoprazole plus amoxicillin versus high dose of lansoprazole plus amoxicillin and clarithromycin for Helicobacter pylori infection [abstract]. Gastroenterology 108: 1995: 68
240. Lamouliatte H, Cayla R, Zerbib F, et al. Triple therapy with proton pump inhibitor: amoxicillin and clarithromycin for Helicobacter pylori eradication [abstract]. Gastroenterology 1995; 108: A143
241. Mones J, Ricart E, Sainz S. Helicobacter pylori eradication. Omeprazole amoxicillin and clarithromycin: 1 week vs 2 weeks [abstract]. Gastroenterology 1996; 110 Suppl. 1: A261
242. Lamouliatte H, Cayla R, Talbi P, et al. Randomised study comparing two seven days triple therapies with lansoprazole and low dose of clarithromycin plus amoxicillin or tinidazole for Helicobacter pylori eradication [abstract]. Gastroenterology 1996; 110 Suppl. 1: A170
243. Lind T, Veldhuyzen van Zanten SJO, Unge P, et al. The Mach-1 Study: optimal one-week treatment for H. pylori defined [abstract]? Gut 1995; 37 Suppl. 1 A 4: 15
244. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996; 91: 246-57
245. Logan RPH, Gummett PA, Misiewicz JJ, et al. One week's anti-Helicobacter pylori treatment for duodenal ulcer. Gut 1994; 35: 15-8
246. Van Deventer GM, Elashoff JE, Reedy TJ, et al. A randomized study of maintenance therapy with ranitidine to prevent the recurrence of duodenal ulcer. N Engl J Med 1989; 320: 1113-9
247. Sontag SJ. ACG Committee on FDA related matters. Current status of maintenance therapy in peptic ulcer disease. Am J Gastroenterol 1988; 83: 607-13
248. Richardson CT. Gastric ulcer. In: Sleisenger MH, Fordtran JS, editors. Gastrointestinal disease: pathophysiology, diagnosis, management. 4th ed. Philadelphia: Saunders, 1989: 879-909
249. Graham DY. Complication of peptic ulcer disease and indications for surgery. In: Sleisenger MH, Fordtran JS, editors. Gastrointestinal disease: pathophysiology, diagnosis, management. 4th ed. Philadelphia: Saunders, 1989: 925-38
250. Bloom BS, Fox NA, Jacobs J. Patterns of care and expenditures by California Medicaid for peptic ulcer and other acid related diseases. J Clin Gastroenterol 1989; 11: 615-20
251. Graham DY, Genta RM. Reinfection with H. pylori. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori: basic mechanisms to clinical cure. Dordrecht: Kluwer, 1994: 113-20
252. Borody TJ, Cole P, Noonan S, et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med J Aust 1989; 151: 431-5
253. Borody T, Andrews P, Manusco N, et al. Helicobacter pylori reinfection 4 years post-eradication [letter]. Lancet 1992; 339: 1295
254. Patchett S, Beattie S, Leen E, et al. Helicobacter pylori and duodenal ulcer recurrence. Am J Gastroenterol 1992; 87: 24-7
255. Forbes GM, Glaser ME, Cullen DJE, et al. Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up. Lancet 1994; 343: 258-60
256. Graham DY, Hepps KS, Ramirez FC, et al. Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. Scand J Gastroenterol 1993; 28: 939-42
257. Rokkas T, Karameris A, Mavrogeorgis A, et al. Eradication of Helicobacter pylori reduces the possibility of rebleeding in peptic ulcer disease. Gastrointest Endosc 1995; 41: 1-4
258. Jaspersen D, Koerner T, Schorr W, et al. Helicobacter pylori eradication reduces the rate of rebleeding in ulcer hemorrhage. Gastrointest Endosc 1995; 41: 5-7
259. Labenz J, Börsch G. Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse. Digestion 1994; 55: 19-23
260. Wilhelmsen I, Berstad A. Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. Scand J Gastroenterol 1994; 29: 874-9
261. Reilly TG, Ayres RCS, Poxon V, et al. Helicobacter pylori eradication in a clinical setting: success rates and the effect on the quality of life in peptic ulcer. Aliment Pharmacol Ther 1995; 9: 483-90
262. Sonnenberg A, Townsend WF. Costs of duodenal ulcer therapy with antibiotics. Arch Intern Med 1995; 155: 922-8
263. Vakil N, Fennerty MB. Cost-effectiveness of treatment regimes tor the eradication of Helicobacter pylori in duodenal ulcer. Am J Gastroenterol 1996; 91: 239-45
264. O'Brien B, Goeree R, Mohamed AH, et al. Cost-effectiveness of Helicobacter pylori eradication for the long term management of duodenal ulcer in Canada. Arch Intern Med 1995; 155: 1958-64
265. Yamada T, Ahnen D, Alpers DH, et al. Helicobacter pylori in peptic ulcer disease. JAMA 1994; 272: 65-9
266. Talley NJ. A relationship between Helicobacter pylori and non-ulcer dyspepsia: is there enough data to know? Eur J Gastroenterol Hepatol 1994; 6: 567-70
267. Holtmann G, Goebell H, Holtmann M. Dyspepsia in healthy blood donors: pattern of symptoms and association with Helicobacter pylori. Dig Dis Sci 1994; 39: 1090-8
268. Kemmer TP, Dominguez-Munoz JE, Klingel H. The association between non-ulcer dyspepsia and Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1994; 6: 571-7
269. Marshall BJ, Warren JR. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984; 1: 1311-5
270. Rokkas T, Pursey C, Uzoechina E, et al. Campylobacter pylori and non-ulcer dyspepsia. Am J Gastroenterol 1987; 82: 1149-52
271. Schubert TT, Schubert AB, Ma CK. Symptoms, gastritis and Helicobacter pylori in patients referred for endoscopy. Gastrointest Endosc 1992; 38: 357-60
272. Patchett S, Beattie S, Leen E, et al. Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia. BMJ 1991; 303: 1238-40
273. Sabbatini F, Castiglione F, Piai G, et al. The long-term outcome of dyspeptic patients after Helicobacter pylori eradication [abstract]. Gastroenterology 1993; 104: A182
274. O'Morain, Gilvarry J. Eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Scand J Gastroenterol 1993; 28 Suppl. 196: 30-3
275. Trespi E, Broglia F, Villani L, et al. Distinct profiles of gastritis in dyspepsia subgroups. Scand J Gastroenterol 1994; 29: 884-8
276. McCarthy C, Patchett S, Collins RM, et al. Long term prospective study of Helicobacter pylori in non-ulcer dyspepsia. Dig Dis Sci 1995; 40: 114-9
277. Talley NJ. A critique of therapeutic trials in Helicobacter pylori-positive functional dyspepsia. Gastroenterology 1994; 106: 1174-83